Bayesian small area cluster analysis of neural tube defects in Newfoundland

Canadian Journal of Public Health

Volumn 97, Issue 5, 2006, Pages 393-397

  Sloka, J Scott ^a,c   Crowley, Marian ^a   Fernandez, Bridget ^a   Maroun, Falah ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Health Sciences Centre   (Canada)

^c 108 Moss Heather Drive ^*  (Canada)

Author keywords

Cluster analysis; Epidemiology; Neural tube defects

Indexed keywords

FOLIC ACID;

ARTICLE; BAYES THEOREM; CANADA; CHILDBIRTH; CLUSTER ANALYSIS; CONTROLLED STUDY; DYSRAPHISM; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEURAL TUBE DEFECT; NEWBORN; PUBLIC HEALTH; RISK ASSESSMENT; STILLBIRTH;

EID: 33750289220     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405349     Document Type: Article

References (35)

1. Gos M, Szpecht-Potocka A. Genetic basis of neural tube defects. I. Regulatory genes for the neurulation process. J Appl Genet 2002;43(3):343-50.
2. Stevenson RE, Allen WP, Pai GS, Best R, Seaver LH, Dean J, et al. Decline in prevalence of neural tube defects in a high-risk region of the United States. Pediatrics 2000;106(4):677-83.
3. Boone D, Parsons D, Lachmann SM, Sherwood T. Spina bifida occulta: Lesion or anomaly? Clin Radiol 1985;36(2):159-61.
4. Fidas A, MacDonald HL, Elton RA, Wild SR, Chisholm GD, Scott R. Prevalence and patterns of Spina bifida occulta in 2707 normal adults. Clin Radiol 1987;38(5):537-42.
5. Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. Lancet 2004;364(9448):1885-95.
6. Wald N. Folic acid and the prevention of neural tube defects. Ann N Y Acad Sci 1993;678:112-29.
7. Moore LL, Bradlee ML, Singer MR, Rothman KJ, Milunsky A. Folate intake and the risk of neural tube defects: An estimation of dose-response. Epidemiology 2003;14(2):200-5.
8. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 1995;274(21):1698-702.
9. Hunter AG. Neural tube defects in Eastern Ontario and Western Quebec: Demography and family data. Am J Med Genet 1984;19(1):45-63.
10. Demenais F, Le Merrer M, Briard ML, Elston RC. Neural tube defects in France: Segregation analysis. Am J Med Genet 1982;11(3):287-98.
11. Finnell RH, Gould A, Spiegelstein O. Pathobiology and genetics of neural tube defects. Epilepsia 2003;44(Suppl 3):14-23.
12. Ray JG, Blom HJ. Vitamin B12 insufficiency and the risk of fetal neural tube defects. QJM 2003;96(4):289-95.
13. Lammer EJ, Sever LE, Oakley GP, Jr. Teratogen update: Valproic acid. Teratology 1987;35(3):465-73.
14. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: A meta-analysis of 1255 exposures. Reprod Toxicol 2002;16(1):9-17.
15. McLeod L, Ray JG. Prevention and detection of diabetic embryopathy. Community Genet 2002;5(1):33-39.
16. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999;341(20):1485-90.
17. Wu J, Wang J, Meng B, Chen G, Pang L, Song X, et al. Exploratory spatial data analysis for the identification of risk factors to birth defects. BMC Public Health 2004;4(1):23.
18. Nevin NC, Weatherall JAC. Illustrated Guide to Malformations of the Central Nervous System at Birth. Edinburgh: Churchill Livingstone, 1983.
19. McDonnell RJ, Johnson Z, Delaney V, Dack P. East Ireland 1990-1994: Epidemiology of neural tube defects. J Epidemiol Community Health 1999;53(12):782-88.
20. Mollie A, Richardson S. Empirical Bayes estimates of cancer mortality rates using spatial models. Stat Med 1991;10(1):95-112.
21. Besag J. Spatial interaction and the statistical analysis of lattice system. J R Stat Soc B 1974;36:192-236.
22. Gilks WR, Clayton DG, Spiegelhalter DJ. Modelling complexity: Applications of Gibbs sampling in medicine. JR Stat Soc B 1993;55:39-102.
23. Bernardinelli L, Montomoli C. Empirical Bayes versus fully Bayesian analysis of geographical variation in disease risk. Stat Med 1992;11(8):983-1007.
24. Clayton D, Kaldor J. Empirical Bayes estimates of age-standardized relative risks for use in disease mapping. Biometrics 1987;43(3):671-81.
25. Geman S, Geman D. Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images. IEE Trans Pattern Anal Machine Intel 1984;6:721-41.
26. Spiegelhalter DJ, Thomas A, Best NG, Gilks WR. BUGS: Bayesian inference using Gibbs sampling, Version 0.5. Cambridge: Medical Research Council Biostatistics Unit, 1996.
27. Besag J, York JC, Mollie A. Bayesian image restoration with two applications in spatial statistics. Ann Inst Stat Math 1991;43:1-59.
28. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993;88:9-25.
29. Geweke J. Evaluating the accuracy of sampling-based approaches to calculating marginal densities. J Am Stat Assoc 1990;85:398-409.
30. Best NG, Cowles MK, Vines SK. CODA: Convergence diagnosis and output analysis software for Gibbs sampling output, Version 0.30. Cambridge: Medical Research Council Biostatistics Unit, 1995.
31. Bernardinelli L, Clayton D, Montomoli C. Bayesian estimates of disease maps: How important are priors? Stat Med 1995;14(21-22):2411-31.
32. Johnson GD. Small area mapping of prostate cancer incidence in New York State (USA) using fully Bayesian hierarchical modelling. Int J Health Geogr 2004;3(1):29.
33. Rothman KJ. A sobering start for the cluster busters' conference. Am J Epidemiol 1990;132 (1 Suppl):S6-S13.
34. Martin LJ, Crawford MH, Koertvelyessy T, Keeping D, Collins M, Huntsman R. The population structure of ten Newfoundland outports. Hum Biol 2000;72(6):997-1016.
35. Nevin NC, Johnston WP, Merrett JD. Influence of social class on the risk of recurrence of anencephalus and spina bifida. Dev Med Child Neurol 1981;23(2):155-59.